Pancreatic Diseases Clinical Trial
Official title:
Influence of the Endoscopist Case Volumen on Endoscopic Retrograde CholangioPanceratography Outcomes
Retrospective analysis on a prospective database that analyzes the influence of the number of endoscopists on the Endoscopic Retrograde CholangioPanceratography result.
The number of Endoscopic Retrograde CholangioPanceratographys (ERCP) performed annually by an endoscopist has been shown to influence the outcomes of the procedure, especially on the papillary cannulation rate and the adverse effects rate. The number of ERCPs performed annually by each endoscopist is directly related to the number of endoscopists who perform this procedure, since the total number of ERCPs performed annually at each center is usually constant. The hypothesis of this study is that the number of endoscopists who perform ERCP in a hospital influences the results of the procedure, so that the fewer the number of endoscopists the better the results. To evaluate this hypothesis, the investigators have designed a retrospective study analyzing data from a prospectively filled database, which includes all ERCPs performed in our center from September 2013 to June 2020. For organizative reasons unrelated to the endoscopy unit, in the center it has beed progressively reduced the number of endoscopists who perform ERCP, starting from 5 endoscopists at the beginning of the study to 3 endoscopists at the end of the study inclusion period. In fact, three different periods of similar duration can be distinguished: September 2013 to August 2015 (5 endoscopists), September 2015 to December 2017 (4 endoscopists) and January 2018 to June 2020 (3 endoscopists). The outcomes obtained with ERCP in these three periods will be analyzed and compared, assessing the cannulation rate and the adverse effects rate as the main comparison parameters. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04205058 -
Coffee After Pancreatic Surgery
|
N/A | |
| Completed |
NCT02971579 -
A Register on the Quality of ERCP and Training of Endoscopists in Italy
|
||
| Not yet recruiting |
NCT01900938 -
Comparison Between Continuous Infusion and Intermittent Bolus Injection of Propofol for Deep Sedation During ERCP
|
N/A | |
| Completed |
NCT01427725 -
Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency
|
||
| Not yet recruiting |
NCT05954221 -
Red Cell Lysis Buffer Application Versus Conventional Sample Processing in EUS-FNB
|
N/A | |
| Enrolling by invitation |
NCT02471170 -
Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases
|
||
| Recruiting |
NCT04259580 -
Calgary Registry for Advanced and Therapeutic Endoscopy
|
||
| Recruiting |
NCT04291651 -
UCSF PANC Cyst Registry
|
||
| Enrolling by invitation |
NCT03234543 -
Remote Ischemic Conditioning in Abdominal Surgery
|
N/A | |
| Completed |
NCT02916199 -
Primary Needle Knife Fistulotomy Versus Conventional Cannulation Method
|
N/A | |
| Completed |
NCT03717298 -
Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
|
Phase 2 | |
| Recruiting |
NCT03334708 -
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
|
||
| Recruiting |
NCT05249400 -
Effect of Off-site Assistance on Success Rate of Selective Cannulation During hands-on ERCP Training
|
N/A | |
| Recruiting |
NCT05824403 -
PAncreatic Disease Cohort of TOuLouse
|
||
| Active, not recruiting |
NCT03269994 -
Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
|
Phase 3 | |
| Enrolling by invitation |
NCT04329039 -
Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics
|
Phase 2/Phase 3 | |
| Completed |
NCT03198871 -
IV Acetaminophen for Post-Operative Pain Management in Enhanced Recovery After Surgery (ERAS) Population
|
Phase 4 | |
| Completed |
NCT02337673 -
Screening of Postoperative Pulmonary Complications by Electrical Impedance Tomography
|
||
| Completed |
NCT01964430 -
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
|
Phase 3 | |
| Completed |
NCT02739074 -
Effectiveness of Metal Protheses Covered in "Diabolo" in Treatment of Necrosis of Origin Pancreatic: Trial "DIABOLOPIG"
|